1 MT vs CT: 28 day survival 10779969378958811223 10469398678268011223 Number at risk CT MT 868 779 0 25 50 75 100 051015202528 day % Surviving Monotherapy.

Slides:



Advertisements
Similar presentations
The Duration of Hypotension Prior to Initiation of Effective Antimicrobial Therapy is the Critical Determinant of Survival in Human Septic Shock Anand.
Advertisements

Serum Lactate Post-Antibiotic antibiotic † † * * Kumar et al. J Infect Dis 2006; 193:
Michael Baram Medical Critical Care. SevereSepsis Relationship Between SIRS, Sepsis and Severe Sepsis Bone RC, et al. Chest 1992;101: Vincent.
1 Severity of illness (APACHE II score ≥ 25) stratified by RIFLE category in septic shock NoneRiskInjuryFailure.
1 Kumar et al, Chest 2009; 136:1237– Impact of Appropriateness of Initial Antimicrobial Therapy on Survival from Septic Shock Kumar et al, Chest.
1 Kumar et al. CCM. 2006:34: Cumulative Initiation of Effective Antimicrobial Therapy and Survival in Septic Shock time from hypotension onset.
Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
Systematic review + meta-analysis: 69 (quasi-)randomised trials: N=7,863 pts with sepsis: any BL monoTx vs any combination of BL + AG: N (studies) : same.
David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
NSTE Acute Coronary Syndromes
Dr Alex Hieatt, EM Consultant MEHT Dr Ron Daniels, Chair of the UK Sepsis Trust and Global Sepsis Alliance (Slides with permission.)
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Preventing Sepsis in Wales
Date of download: 9/18/2016 From: Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy.
Upfront Combination Therapy vs Step-Up Approach for PAH:
Surgical ICU, Heart Institute University of São Paulo
The relationship among infection, sepsis, and the systemic inflammatory response syndrome (SIRS). (Modified from the American College of Chest Physicians/Society.
The Duration of Hypotension Prior to Initiation of Effective Antimicrobial Therapy is the Critical Determinant of Survival in Human Septic Shock Anand.
‘TAP THE TAZ’ Liz Casey A/Resuscitation & EWS Training Officer
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Survival probability (%)
Sekeres MA et al. Proc ASH 2015;Abstract 908.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis
IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.
 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
Stupp Trial: Improved survival with TMZ Chemotherapy
Intra-Abdominal Candidiasis, Candida peritonitis
Avilla et al, 2009.
Improving Outcomes for Severe Sepsis and Septic Shock: Tools for Early Identification of At-Risk Patients and Treatment Protocol Implementation  Emanuel.
PREMIER: Rate of hypertension at 18 months
Examining the Latest Evidence in PAH
Antimicrobial Therapy for Life-threatening Infections: Speed is Life
ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
The laws of acute otitis media
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Recognising sepsis and taking action
Optimizing Outcomes in Sepsis Dr. Anand Kumar
Kaplan-Meier curves for overall survival (OS) probability.
Enrollment and Outcomes
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Saving the Day.
Community-acquired pneumonia in adults
Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.
Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.
Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.
Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.
Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.
(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.
Kaplan-Meier curves depicting the probability of survival from study enrollment in patients receiving conventional chest physical therapy (CCPT) (solid.
Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.
Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.
Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.
Relative risk of suffering clinically measurable levels of general anxiety and depression following a false-positive mammogram compared to a normal mammogram,
Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.
Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.
Mortality rate according to our integrated index that combines DH and exercise capacity. Mortality rate according to our integrated index that combines.
Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.
CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.
Presentation transcript:

1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy (MT) Combination Therapy (CT) Log-rank p-value: Kumar et al, Crit Care Med 2009 (in press)

2 MT vs CT: 28 day pressor liberation MT CT Number at risk Pressor dependence (%) Time (days) Log rank p-value = 0.03 Monotherapy (MT) Combination Therapy (CT) Kumar et al, Crit Care Med 2010;38:1773–85

3 Combination vs Monotherapy: Primary Antibiotic Kumar et al, Crit Care Med 2010;38:1773–85

4 Combination vs Monotherapy: Organisms Kumar et al, Crit Care Med 2010;38:1773–85

5 Combination vs Monotherapy: Secondary Antibiotic Kumar et al, Crit Care Med 2010;38:1773–85

6 Combination vs Monotherapy: Clinical Syndrome Kumar et al, Crit Care Med 2010;38:1773–85